Christos S. Karapetis

27.0k total citations · 5 hit papers
314 papers, 11.2k citations indexed

About

Christos S. Karapetis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Christos S. Karapetis has authored 314 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Oncology, 134 papers in Pulmonary and Respiratory Medicine and 76 papers in Pathology and Forensic Medicine. Recurrent topics in Christos S. Karapetis's work include Colorectal Cancer Treatments and Studies (142 papers), Genetic factors in colorectal cancer (65 papers) and Gastric Cancer Management and Outcomes (62 papers). Christos S. Karapetis is often cited by papers focused on Colorectal Cancer Treatments and Studies (142 papers), Genetic factors in colorectal cancer (65 papers) and Gastric Cancer Management and Outcomes (62 papers). Christos S. Karapetis collaborates with scholars based in Australia, United States and Canada. Christos S. Karapetis's co-authors include Timothy Price, Derek J. Jonker, John Zalcberg, Dongsheng Tu, Niall C. Tebbutt, Chris J. O’Callaghan, Malcolm J. Moore, R. J. Simes, Christiane Langer and Jeremy Shapiro and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Christos S. Karapetis

297 papers receiving 11.0k citations

Hit Papers

K-ras Mutations and Benefit from Cetuximab in Advanced Co... 2007 2026 2013 2019 2008 2007 2010 2015 2014 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
    2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. profile →
  2. Cetuximab for the Treatment of Colorectal Cancer
    2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. profile →
  3. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    2010 573 citations Derek J. Jonker, Dongsheng Tu et al. profile →
  4. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
    2015 464 citations Christos S. Karapetis et al. Annals of Oncology profile →
  5. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
    2014 383 citations Michael J. Sorich, Andrew Rowland et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christos S. Karapetis Australia 42 8.2k 3.8k 2.8k 2.3k 2.0k 314 11.2k
Edith P. Mitchell United States 47 8.8k 1.1× 3.6k 0.9× 1.4k 0.5× 2.7k 1.2× 2.4k 1.2× 205 12.1k
Niall C. Tebbutt Australia 48 9.3k 1.1× 4.4k 1.1× 2.6k 0.9× 2.0k 0.9× 2.7k 1.3× 255 12.8k
Timothy Price Australia 48 10.7k 1.3× 5.0k 1.3× 3.1k 1.1× 2.3k 1.0× 2.8k 1.4× 476 14.8k
Eduardo Díaz‐Rubio Spain 49 8.7k 1.1× 3.5k 0.9× 1.9k 0.7× 2.0k 0.9× 2.0k 1.0× 351 12.0k
Alberto Sobrero Italy 45 9.6k 1.2× 3.9k 1.0× 2.3k 0.8× 1.4k 0.6× 1.7k 0.8× 207 12.1k
Tamas Hickish United Kingdom 45 10.2k 1.2× 4.3k 1.1× 2.3k 0.8× 1.9k 0.8× 1.6k 0.8× 145 13.5k
Thomas H. Cartwright United States 25 7.3k 0.9× 3.0k 0.8× 1.1k 0.4× 1.9k 0.8× 3.4k 1.7× 81 11.2k
Howard S. Höchster United States 56 8.1k 1.0× 3.3k 0.9× 2.0k 0.7× 1.8k 0.8× 2.4k 1.2× 342 12.0k
Paul Ruff South Africa 32 6.4k 0.8× 2.6k 0.7× 1.8k 0.6× 1.2k 0.5× 1.4k 0.7× 155 8.9k
Miriam Koopman Netherlands 41 5.7k 0.7× 1.9k 0.5× 2.0k 0.7× 1.3k 0.6× 1.1k 0.6× 222 8.0k

Countries citing papers authored by Christos S. Karapetis

Since Specialization
Citations

This map shows the geographic impact of Christos S. Karapetis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christos S. Karapetis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christos S. Karapetis more than expected).

Fields of papers citing papers by Christos S. Karapetis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christos S. Karapetis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christos S. Karapetis. The network helps show where Christos S. Karapetis may publish in the future.

Co-authorship network of co-authors of Christos S. Karapetis

This figure shows the co-authorship network connecting the top 25 collaborators of Christos S. Karapetis. A scholar is included among the top collaborators of Christos S. Karapetis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christos S. Karapetis. Christos S. Karapetis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vatandoust, Sina, Luigi Sposato, David A. Wattchow, et al.. (2026). Bowel Function in Survivors of Rectal Cancer Managed with Watch-and-Wait Versus Surgery. Journal of Gastrointestinal Cancer. 57(1). 26–26.
2.
3.
Gupta, Arjun, Christopher J. O’Callaghan, Liting Zhu, et al.. (2024). The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17. JNCI Journal of the National Cancer Institute. 116(8). 1313–1318. 7 indexed citations
4.
Titmuss, Emma, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2024). Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research. 30(6). 1121–1130. 3 indexed citations
5.
6.
Ullah, Shahid, Cynthia Piantadosi, Christos S. Karapetis, et al.. (2023). First-line anti-EGFR or anti-VEGF therapy, tumour sidedness, and survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry.. Journal of Clinical Oncology. 41(4_suppl). 42–42. 1 indexed citations
7.
Deng, Yangqing, Dongsheng Tu, Chris J. O’Callaghan, et al.. (2023). A Bayesian approach for two‐stage multivariate Mendelian randomization with mixed outcomes. Statistics in Medicine. 42(13). 2241–2256. 1 indexed citations
8.
Chen, Nan, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2023). Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.. Journal of Clinical Oncology. 41(4_suppl). 124–124. 1 indexed citations
9.
Ullah, Shahid, Timothy Price, Christos S. Karapetis, et al.. (2023). Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis. ANZ Journal of Surgery. 93(7-8). 1847–1853. 3 indexed citations
10.
Jiang, Di, Hao‐Wen Sim, Lillian L. Siu, et al.. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer. 22(4). 457–463.
11.
Bowen, Joanne M., Rachel J. Gibson, Kate R. Secombe, et al.. (2023). Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. Cancer Chemotherapy and Pharmacology. 91(6). 507–521. 3 indexed citations
12.
Hopkins, Ashley M., Michael J. Sorich, Andrew J. McLachlan, et al.. (2023). Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer. JCO Precision Oncology. 7(7). e2200538–e2200538. 3 indexed citations
13.
Hopkins, Ashley M., Ganessan Kichenadasse, Ross A. McKinnon, et al.. (2021). Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. British Journal of Cancer. 126(1). 42–47. 51 indexed citations
14.
Hopkins, Ashley M., Ganessan Kichenadasse, Elizabeth Garrett‐Mayer, et al.. (2020). Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. Clinical Cancer Research. 26(13). 3280–3286. 29 indexed citations
15.
Loree, Jonathan M., Dongsheng Tu, Derek J. Jonker, et al.. (2020). Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clinical Cancer Research. 27(1). 52–59. 19 indexed citations
16.
Townsend, Amanda, Niall C. Tebbutt, Christos S. Karapetis, et al.. (2018). Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research. 24(16). 3838–3844. 6 indexed citations
17.
Miller, Michelle, Stephanie Zrim, Sharon Lawn, et al.. (2016). A Pilot Study of Self-Management-based Nutrition and Physical Activity Intervention in Cancer Survivors. Nutrition and Cancer. 68(5). 762–771. 3 indexed citations
18.
Schmoll, Hans‐Joachim, David Cunningham, Alberto Sobrero, et al.. (2012). Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). Journal of Clinical Oncology. 30(29). 3588–3595. 163 indexed citations
19.
Karapetis, Christos S., et al.. (2007). Efficacy of aprepitant in management of chemotherapy‐induced nausea and vomiting. Internal Medicine Journal. 37(4). 247–250. 4 indexed citations
20.
Karapetis, Christos S., et al.. (1999). THE TREATMENT OF METASTATIC COLORECTAL CANCER. International Journal of Clinical Practice. 53(4). 287–294. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edith P. Mitchell Breakdown of academic impact, for papers by Niall C. Tebbutt Breakdown of academic impact, for papers by Timothy Price Breakdown of academic impact, for papers by Eduardo Díaz‐Rubio Breakdown of academic impact, for papers by Alberto Sobrero Breakdown of academic impact, for papers by Tamas Hickish Breakdown of academic impact, for papers by Thomas H. Cartwright Breakdown of academic impact, for papers by Howard S. Höchster Breakdown of academic impact, for papers by Paul Ruff Breakdown of academic impact, for papers by Miriam Koopman
Rankless by CCL
2026